Manuela A. Hoffmann

ORCID: 0000-0002-8867-5525
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Radiopharmaceutical Chemistry and Applications
  • Cancer, Lipids, and Metabolism
  • Medical Imaging Techniques and Applications
  • Medical Imaging and Pathology Studies
  • Bladder and Urothelial Cancer Treatments
  • Peptidase Inhibition and Analysis
  • Urologic and reproductive health conditions
  • Orthopaedic implants and arthroplasty
  • Hip disorders and treatments
  • Health and Lifestyle Studies
  • Urological Disorders and Treatments
  • Radiomics and Machine Learning in Medical Imaging
  • Occupational Health and Performance
  • Effects of Radiation Exposure
  • Heavy metals in environment
  • Cardiovascular Syncope and Autonomic Disorders
  • SARS-CoV-2 and COVID-19 Research
  • Thyroid Cancer Diagnosis and Treatment
  • Soil Carbon and Nitrogen Dynamics
  • Cannabis and Cannabinoid Research
  • Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Urinary Tract Infections Management
  • Statistical Methods in Clinical Trials

University Medical Center of the Johannes Gutenberg University Mainz
2017-2025

Johannes Gutenberg University Mainz
2017-2025

Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie
2025

Bundeswehr
2023-2025

Federal Ministry of Defence
2019-2023

Universitätsmedizin Greifswald
2020-2022

Zentrum für Luft- und Raumfahrtmedizin der Luftwaffe
2022

Bundeswehrzentralkrankenhaus Koblenz
2017-2020

Klinik und Poliklinik für Nuklearmedizin
2020

Bundeswehr Joint Medical Service
2017-2019

In biochemical recurrence of prostate cancer (BCR), prompt tumor localization guides early treatment, potentially improving patient outcomes. Gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography (68Ga-PSMA-11 PET/CT) detection rates lesions suspicious for are well known to rise along with antigen (PSA) concentration. However, published data limited regarding very low values (≤0.2 ng/mL). We retrospectively analyzed ~7-year "real-world" experience...

10.3390/cancers15051376 article EN Cancers 2023-02-21

A high vaccination rate of older and particularly chronically ill people against coronavirus disease-2019 (COVID-19) is likely one the most important factors in containing pandemic. When Germany’s campaign started on December 2020, prioritization was initially carried out starting with population groups. Side effect rates 1065 individuals who had received first dose messenger ribonucleic acid (mRNA) vaccine BNT162b2 Tozinameran from BioNTech/Pfizer three weeks earlier were examined...

10.3390/vaccines9080911 article EN cc-by Vaccines 2021-08-16

In patients with metastatic castration-resistant prostate cancer (mCRPC) treated prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT), the predictive value of PSMA PET/CT-derived response is still under investigation. Early molecular imaging based on total viable tumor burden and its association overall survival (OS) was explored in this study.Sixty-six mCRPC who received [177Lu]Lu-PSMA-617 RLT within a prospective patient registry (REALITY Study, NCT04833517) were...

10.1007/s00259-021-05594-8 article EN cc-by European Journal of Nuclear Medicine and Molecular Imaging 2021-11-02

This study aimed to compare the diagnostic performance of [18F]PSMA-1007 positron emission tomography/computed tomography (PET/CT) (18F-PSMA) and [68Ga]Ga-PSMA-11 PET/CT (68Ga-PSMA) by identifying prostate-specific antigen (PSA) threshold levels for optimal detecting recurrent prostate cancer (PC) both methods. Retrospectively, included 264 patients. The performances 18F-PSMA 68Ga-PSMA in relation pre-scan PSA were assessed receiver operating characteristic (ROC) curve. showed PC-lesions...

10.3390/cancers14061479 article EN Cancers 2022-03-14

Radiolabeled prostate-specific membrane antigen (PSMA) has proven to be a highly accurate method detect recurrence and metastases of prostate cancer, but only sparse data is available about its performance in the diagnosis clinically significant primary cancer.We compared 68Ga-PSMA-11 PET/CT 25 patients with 18FEC 40 suspected carcinoma based on an increased PSA level.The results were histopathologic Gleason Score (GS) biopsies.The revealed suspect prostatic lesions (maximum standardized...

10.18632/oncotarget.22441 article EN Oncotarget 2017-11-14

Als Präventionsmaßnahme insbesondere zur Vermeidung kardiovaskulärer Erkrankungen wurde im Sanitätsunterstützungszentrum (SanUstgZ) Cochem die medizinische Betreuung durch Einführung eines Ernährungsberatungskonzeptes unterstützt. Die Studie zielte auf Fragestellung ab, wie eine Standardisierung der Ernährungsberatung in regionalen sanitätsdienstlichen Versorgung (RegSanVers) Bundeswehr erfolgen kann und erste Erkenntnisse über einen präventivmedizinischen Nutzengewonnen werden können. In...

10.1007/s40664-024-00568-7 article DE cc-by-nc-nd Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie 2025-01-08

Routine [68Ga]Ga-PSMA-11 PET/CT (one hour post-injection) has been shown to accurately detect prostate cancer (PCa) lesions. The goal of this study is evaluate the benefit a dual-time point imaging modality for staging and restaging PCa patients. Biphasic 233 patients, who underwent early late scans (one/three hours post-injection), were retrospectively studied. Tumor uptake biphasic lesion detection 215 biochemically recurrent patients previously treated localized (prostatectomized...

10.3390/cancers12102788 article EN Cancers 2020-09-28

44Sc has been increasingly investigated as a potential alternative to 68Ga in the development of tracers for positron emission tomography (PET). The lower mean energy (0.63 MeV) compared (0.83 can result better spatial image resolutions. However, high-energy γ-rays (1157 keV) are emitted at high rates (99.9%) during decay, which reduce quality. Therefore, we impact these physical properties and performed an unbiased performance evaluation with different imaging phantoms (image quality...

10.1186/s40658-020-0286-3 article EN cc-by EJNMMI Physics 2020-03-12

In this study, we investigated upregulation of prostate-specific membrane antigen (PSMA) by enzalutamide in a cohort (n = 30) patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Patients were examined [68Ga]Ga-PSMA-11 PET/CT pre- and post-enzalutamide medication (mean 13 ± 7 days). Imaging results compared based on quantification whole-body PSMA tumor burden: total lesion (TLP) normalized TLP values to liver (TLP-LR) parotid gland (TLP-PR). addition, lesion-based...

10.3390/cancers14071696 article EN Cancers 2022-03-26

Hybrid imaging with prostate-specific membrane antigen (PSMA) is gaining importance as an increasingly meaningful tool for prostate cancer (PC) diagnostics and a guide therapy decisions. This study aims to investigate compare the performance of [18F]PSMA-1007 (18F-PSMA) [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography (68Ga-PSMA) in initial staging PC patients.The data 88 biopsy-proven patients were retrospectively evaluated. PSMA-avid lesions compared histopathologic...

10.3390/jcm11175064 article EN Journal of Clinical Medicine 2022-08-29

68Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT) is commonly used for restaging recurrent prostate cancer (PC) in European clinical practice. The goal of this study to determine the optimum time performing these PET/CT scans a large cohort patients by identifying prostate-specific-antigen (PSA) and PSA kinetics thresholds detecting localizing PC. This retrospective analysis includes 581 with biochemical recurrence (BC) definition. performance relation value at scan as...

10.3390/cancers12020398 article EN Cancers 2020-02-08

// Manuela A. Hoffmann 1 , 2 3 Hans-Georg Buchholz Helmut J. Wieler Thomas Höfner 4 Jonas Müller-Hübenthal 5 Ludwin Trampert 6 and Mathias Schreckenberger Department of Occupational Health Safety, Supervisory Center for Radiation Protection, Federal Ministry Defense, Bonn 53123, Germany Clinic Nuclear Medicine, Johannes Gutenberg-University, Mainz 55101, Bundeswehr Central Hospital, Koblenz 56072, Urology, Practice Radiology Praxis im KölnTriangle, Köln 50679, Klinikum Mutterhaus der...

10.18632/oncotarget.27239 article EN Oncotarget 2019-10-22

The aim of this study was to assess body mass index (BMI) and the prevalence overweight obesity at entry release service German Armed Forces related associations duration. In a cohort study, 85,076 paired BMI data sets (entry service) soldiers (5.4% females) between 2010 2022 were analyzed retrospectively alterations (BMI ≥ 25) 30) after durations ≤2 years, 2−5 or ≥5 years. Between 2022, we observed trend for increases about 0.5 kg/m2 (X2 = 27.104, p 0.007). differed significantly 7622.858,...

10.3390/healthcare11020225 article EN Healthcare 2023-01-11

Abstract Background Obesity rates are rising in the armed forces of Western democratic countries, impacting military readiness and health. This highlights need for preventive health risk assessments countermeasures. Methods Using mandatory examination data from 2018 to 2022, we analyzed prevalence obesity, risks, associated specific factors (rank unit) 43,214 soldiers German Armed Forces. Statistical methods included χ 2 contingencies binary logistic regressions. Results The obesity (BMI ≥...

10.1186/s12995-024-00411-y article EN cc-by Journal of Occupational Medicine and Toxicology 2024-04-15

The aim of this retrospective study was to identify pre-therapeutic predictive laboratory and molecular imaging biomarkers for response overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT). Pre-therapeutic [68Ga]Ga-PSMA-11 PET/CT data n = 102 mCRPC receiving [177Lu]Lu-PSMA-617 RLT within a prospective registry (REALITY Study, NCT04833517) were analyzed including...

10.3390/cancers16152670 article EN Cancers 2024-07-26

Huntington's disease (HD) is a rare, genetic neurodegenerative disorder often presenting with emotional, cognitive and behavioral abnormalities before manifestation of defining motor symptoms. Cognitive impairment frequent clinical feature caused by different dementia subtypes. Imaging cortical subcortical glucose metabolism via 18F-FDG PET/CT can help to discriminate the underlying disease. The patient 54-year old man progressive mild orofacial dyskinesia. brain revealed severe bilateral...

10.1186/s12883-019-1311-9 article EN cc-by BMC Neurology 2019-05-01

Abstract Anhand von Lysimeteruntersuchungen der Bodenlösung, Untersuchungen Bodenfestphase und unter Verwendung Modellvorstellungen wird die Möglichkeit demonstriert, Zusammensetzung Bodenlösung teilweise aus den Eigenschaften vorherzusagen. Als Vorhersageparameter erweist sich im NH 4 CI‐Extrakt ermittelte Aluminium‐(Basen)sättigung Kationenaustauscher als besonders geeignet. Der Parameter zeigt ausgeprägte Tiefengradienten, charakteristische Zustandsgrößen jeweiligen Waldökosysteme gelten...

10.1002/jpln.1996.3581590111 article DE Zeitschrift für Pflanzenernährung und Bodenkunde 1996-02-01

Performance of a periacetabular osteotomy (PAO) using minimally invasive approach for three-dimensional correction the acetabular position.Symptomatic developmental dysplasia hip in adolescents and adults.Advanced osteoarthritis hip, incongruence joint surfaces.A is performed via approach.In total, 39 patients were followed up 3.5 (3-4.5) years. The lateral center-edge angle Wiberg increased significantly from 16.1° (7-24°) to 30.5° (25-37°) (p < 0.0001), index changed 13.2° (2-25.3°) 2.8°...

10.1007/s00064-022-00771-w article DE cc-by Operative Orthopädie und Traumatologie 2022-05-18
Coming Soon ...